• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MYX
Click for more information
7.18% $4.48

MAYNE PHARMA GROUP LIMITED - Announcements

Market Cap $393.8M  ! watchlist Created with Sketch. Add to my watchlist

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused... Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MYX 2016 Sustainability Report08/06/17
MYX Appendix 3B26/05/17
MYX Change in substantial holding24/05/17
MYX Appendix 3B22/05/17
MYX Change of Director's Interest Notice11/05/17
MYX Appendix 3B10/05/17
MYX Appendix 3B08/05/17
MYX Response to ASX Aware LetterPRICE SENSITIVE04/05/17
MYX Becoming a substantial holder03/05/17
MYX Ceasing to be a substantial holder from CGF03/05/17
MYX Clarification statementPRICE SENSITIVE02/05/17
MYX Investor Day - Presentation01/05/17
MYX Becoming a substantial holder from CGF28/04/17
MYX Mayne Pharma to host Investor Day on May 1st, 201726/04/17
MYX Becoming a substantial holder11/04/17
MYX Appendix 3B10/04/17
MYX Appendix 3B28/03/17
MYX Change of Director's Interest Notice17/03/17
MYX Ceasing to be a substantial holder13/03/17
MYX Becoming a substantial holder09/03/17
MYX Mayne Pharma appoints new Group CFO and Company Secretary09/03/17
MYX Mayne Pharma acquires rights to generic Duragesic in the USPRICE SENSITIVE09/03/17
MYX Change of Director's Interest Notice08/03/17
MYX Appendix 3B06/03/17
MYX License and supply agreement for generic Nuvaring in the USPRICE SENSITIVE28/02/17
MYX 2017 Half Year Investor Presentation24/02/17
MYX 2017 Half Year Media ReleasePRICE SENSITIVE24/02/17
MYX Half Yearly Report and AccountsPRICE SENSITIVE24/02/17
MYX Appendix 3B20/02/17
MYX Mayne Pharma launches Butalbital / APAP tablets in the USPRICE SENSITIVE16/02/17
MYX Mayne Pharma announces leadership changes16/01/17
MYX Mayne Pharma launches Amiodarone 100mg tabletsPRICE SENSITIVE13/01/17
MYX Appendix 3B12/01/17
MYX Change of Director's Interest Notice11/01/17
MYX Mayne Pharma launches Fabior and Sorilux in the USPRICE SENSITIVE11/01/17
MYX Appendix 3B28/12/16
MYX Change of Director's Interest Notice28/12/16
MYX Change of Director's Interest Notice (x4)21/12/16
MYX Appendix 3B21/12/16
MYX Change in substantial holding from CBA21/12/16
MYX Change of Director's Interest Notices (x2)19/12/16
MYX Update on Status of DOJ InvestigationPRICE SENSITIVE16/12/16
MYX Change in substantial holding from CBA13/12/16
MYX Appendix 3B13/12/16
MYX Change in substantial holding12/12/16
MYX Change of Director's Interest Notice12/12/16
MYX Ceasing to be a substantial holder from NAB12/12/16
MYX Appendix 3B09/12/16
MYX Change of Director's Interest Notice07/12/16
MYX Becoming a substantial holder from NAB30/11/16
MYX Results of Annual General Meeting29/11/16
MYX 2016 AGM CEO's Speech29/11/16
MYX 2016 AGM Chairman's Speech29/11/16
MYX IDT:Mayne Pharma Announces U.S. Launch of IDT's Temozolomide22/11/16
MYX UBS Australasia Conference Presentation07/11/16
MYX Update on Status of DOJ InvestigationPRICE SENSITIVE04/11/16
MYX MYX launches generic MS Contin (morphine sulfate) tablets-MYX.AX PRICE SENSITIVE03/11/16
MYX MYX launches generic MS Contin (morphine sulfate) tabletsPRICE SENSITIVE03/11/16
MYX 1st generic proprietary product shipped to US, temozolomide,MYX-IDT.AX PRICE SENSITIVE02/11/16
MYX Becoming a substantial holder from CBA,CBA-MYX.AX 01/11/16
MYX MYX launches generic Entocort EC (Budesonide) capsules-MYX.AX PRICE SENSITIVE27/10/16
MYX Notice of Annual General Meeting/Proxy Form-MYX.AX 17/10/16
MYX Appendix 3B-MYX.AX 11/10/16
MYX Appendix 4G-MYX.AX 07/10/16
MYX 2016 Corporate Governance Statement-MYX.AX 07/10/16
MYX 2016 Annual Report-MYX.AX 07/10/16
MYX Appendix 3B-MYX.AX 29/09/16
MYX Ceasing to be a substantial holder from WBC,WBC-MYX.AX 28/09/16
MYX Appendix 3B-MYX.AX 26/09/16
MYX Change of Director's Interest Notice-MYX.AX 23/09/16
MYX Initial Director's Interest Notice-MYX.AX 23/09/16
MYX Mayne Pharma appoints new Board member-MYX.AX 21/09/16
MYX Change of Director's Interest Notice-MYX.AX 13/09/16
MYX Change in substantial holding from WBC,WBC-MYX.AX 01/09/16
MYX Appendix 3B-MYX.AX 28/08/16
MYX 2016 Full Year Results Investor Presentation-MYX.AX 28/08/16
MYX Appendix 4E, Directors Report and Financial Statements-MYX.AX PRICE SENSITIVE28/08/16
MYX 2016 Full Year Results Media Release-MYX.AX 28/08/16
MYX 2016 Full Year Results Investor Presentation-MYX.AX 26/08/16
MYX 2016 Full Year Results Media Release-MYX.AX 26/08/16
MYX Appendix 4E, Directors Report and Financial Statements-MYX.AX PRICE SENSITIVE26/08/16
MYX Appendix 3B-MYX.AX 25/08/16
MYX Appendix 3B-MYX.AX 22/08/16
MYX Response to ASX Appendix 3Y Query-MYX.AX 19/08/16
MYX Investor Presentation Acquisition of GSK Foam Assets-MYX.AX 18/08/16
MYX MYX announces acquisition of US foam dermatology assets-MYX.AX PRICE SENSITIVE18/08/16
MYX Change of Director's Interest Notice-MYX.AX 16/08/16
MYX Appendix 3B-MYX.AX 11/08/16
MYX Appendix 3B-MYX.AX 04/08/16
MYX Completion of US generic product acquisition from Teva-MYX.AX 03/08/16
MYX MYX announces settlement from patent infringement case-MYX.AX PRICE SENSITIVE29/07/16
MYX Change in substantial holding from WBC,WBC-MYX.AX 27/07/16
MYX Change in substantial holding from WBC,WBC-MYX.AX 27/07/16
MYX Change of Director's Interest Notice-MYX.AX 27/07/16
MYX Ceasing to be a substantial holder from BTT,BTT-MYX.AX 26/07/16
MYX Ceasing to be a substantial holder from BTT,BTT-MYX.AX 26/07/16
MYX Appendix 3B-MYX.AX 22/07/16
MYX Change in substantial holding from BTT,BTT-MYX.AX 21/07/16
MYX Change in substantial holding from BTT,BTT-MYX.AX 21/07/16
MYX Retail Entitlement Offer completion and scale back policy-MYX.AX 20/07/16
MYX 2016 Sustainability Report
08/06/17
MYX Appendix 3B
26/05/17
MYX Change in substantial holding
24/05/17
MYX Appendix 3B
22/05/17
MYX Change of Director's Interest Notice
11/05/17
MYX Appendix 3B
10/05/17
MYX Appendix 3B
08/05/17
MYX Response to ASX Aware Letter
04/05/17PRICE SENSITIVE
MYX Becoming a substantial holder
03/05/17
MYX Ceasing to be a substantial holder from CGF
03/05/17
MYX Clarification statement
02/05/17PRICE SENSITIVE
MYX Investor Day - Presentation
01/05/17
MYX Becoming a substantial holder from CGF
28/04/17
MYX Mayne Pharma to host Investor Day on May 1st, 2017
26/04/17
MYX Becoming a substantial holder
11/04/17
MYX Appendix 3B
10/04/17
MYX Appendix 3B
28/03/17
MYX Change of Director's Interest Notice
17/03/17
MYX Ceasing to be a substantial holder
13/03/17
MYX Becoming a substantial holder
09/03/17
MYX Mayne Pharma appoints new Group CFO and Company Secretary
09/03/17
MYX Mayne Pharma acquires rights to generic Duragesic in the US
09/03/17PRICE SENSITIVE
MYX Change of Director's Interest Notice
08/03/17
MYX Appendix 3B
06/03/17
MYX License and supply agreement for generic Nuvaring in the US
28/02/17PRICE SENSITIVE
MYX 2017 Half Year Investor Presentation
24/02/17
MYX 2017 Half Year Media Release
24/02/17PRICE SENSITIVE
MYX Half Yearly Report and Accounts
24/02/17PRICE SENSITIVE
MYX Appendix 3B
20/02/17
MYX Mayne Pharma launches Butalbital / APAP tablets in the US
16/02/17PRICE SENSITIVE
MYX Mayne Pharma announces leadership changes
16/01/17
MYX Mayne Pharma launches Amiodarone 100mg tablets
13/01/17PRICE SENSITIVE
MYX Appendix 3B
12/01/17
MYX Change of Director's Interest Notice
11/01/17
MYX Mayne Pharma launches Fabior and Sorilux in the US
11/01/17PRICE SENSITIVE
MYX Appendix 3B
28/12/16
MYX Change of Director's Interest Notice
28/12/16
MYX Change of Director's Interest Notice (x4)
21/12/16
MYX Appendix 3B
21/12/16
MYX Change in substantial holding from CBA
21/12/16
MYX Change of Director's Interest Notices (x2)
19/12/16
MYX Update on Status of DOJ Investigation
16/12/16PRICE SENSITIVE
MYX Change in substantial holding from CBA
13/12/16
MYX Appendix 3B
13/12/16
MYX Change in substantial holding
12/12/16
MYX Change of Director's Interest Notice
12/12/16
MYX Ceasing to be a substantial holder from NAB
12/12/16
MYX Appendix 3B
09/12/16
MYX Change of Director's Interest Notice
07/12/16
MYX Becoming a substantial holder from NAB
30/11/16
MYX Results of Annual General Meeting
29/11/16
MYX 2016 AGM CEO's Speech
29/11/16
MYX 2016 AGM Chairman's Speech
29/11/16
MYX IDT:Mayne Pharma Announces U.S. Launch of IDT's Temozolomide
22/11/16
MYX UBS Australasia Conference Presentation
07/11/16
MYX Update on Status of DOJ Investigation
04/11/16PRICE SENSITIVE
MYX MYX launches generic MS Contin (morphine sulfate) tablets-MYX.AX
03/11/16PRICE SENSITIVE
MYX MYX launches generic MS Contin (morphine sulfate) tablets
03/11/16PRICE SENSITIVE
MYX 1st generic proprietary product shipped to US, temozolomide,MYX-IDT.AX
02/11/16PRICE SENSITIVE
MYX Becoming a substantial holder from CBA,CBA-MYX.AX
01/11/16
MYX MYX launches generic Entocort EC (Budesonide) capsules-MYX.AX
27/10/16PRICE SENSITIVE
MYX Notice of Annual General Meeting/Proxy Form-MYX.AX
17/10/16
MYX Appendix 3B-MYX.AX
11/10/16
MYX Appendix 4G-MYX.AX
07/10/16
MYX 2016 Corporate Governance Statement-MYX.AX
07/10/16
MYX 2016 Annual Report-MYX.AX
07/10/16
MYX Appendix 3B-MYX.AX
29/09/16
MYX Ceasing to be a substantial holder from WBC,WBC-MYX.AX
28/09/16
MYX Appendix 3B-MYX.AX
26/09/16
MYX Change of Director's Interest Notice-MYX.AX
23/09/16
MYX Initial Director's Interest Notice-MYX.AX
23/09/16
MYX Mayne Pharma appoints new Board member-MYX.AX
21/09/16
MYX Change of Director's Interest Notice-MYX.AX
13/09/16
MYX Change in substantial holding from WBC,WBC-MYX.AX
01/09/16
MYX Appendix 3B-MYX.AX
28/08/16
MYX 2016 Full Year Results Investor Presentation-MYX.AX
28/08/16
MYX Appendix 4E, Directors Report and Financial Statements-MYX.AX
28/08/16PRICE SENSITIVE
MYX 2016 Full Year Results Media Release-MYX.AX
28/08/16
MYX 2016 Full Year Results Investor Presentation-MYX.AX
26/08/16
MYX 2016 Full Year Results Media Release-MYX.AX
26/08/16
MYX Appendix 4E, Directors Report and Financial Statements-MYX.AX
26/08/16PRICE SENSITIVE
MYX Appendix 3B-MYX.AX
25/08/16
MYX Appendix 3B-MYX.AX
22/08/16
MYX Response to ASX Appendix 3Y Query-MYX.AX
19/08/16
MYX Investor Presentation Acquisition of GSK Foam Assets-MYX.AX
18/08/16
MYX MYX announces acquisition of US foam dermatology assets-MYX.AX
18/08/16PRICE SENSITIVE
MYX Change of Director's Interest Notice-MYX.AX
16/08/16
MYX Appendix 3B-MYX.AX
11/08/16
MYX Appendix 3B-MYX.AX
04/08/16
MYX Completion of US generic product acquisition from Teva-MYX.AX
03/08/16
MYX MYX announces settlement from patent infringement case-MYX.AX
29/07/16PRICE SENSITIVE
MYX Change in substantial holding from WBC,WBC-MYX.AX
27/07/16
MYX Change in substantial holding from WBC,WBC-MYX.AX
27/07/16
MYX Change of Director's Interest Notice-MYX.AX
27/07/16
MYX Ceasing to be a substantial holder from BTT,BTT-MYX.AX
26/07/16
MYX Ceasing to be a substantial holder from BTT,BTT-MYX.AX
26/07/16
MYX Appendix 3B-MYX.AX
22/07/16
MYX Change in substantial holding from BTT,BTT-MYX.AX
21/07/16
MYX Change in substantial holding from BTT,BTT-MYX.AX
21/07/16
MYX Retail Entitlement Offer completion and scale back policy-MYX.AX
20/07/16
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$4.48 		Change
0.300(7.18%) 		Mkt cap ! $393.8M
Open High Low Value Volume
$4.22 $4.50 $4.18 $1.134M 259.5K

Buyers (Bids)

No. Vol. Price($)
1 708 $4.43
 

Sellers (Offers)

Price($) Vol. No.
$4.50 1182 1
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
Last
$4.48 		  Change
0.300 ( 7.09 %)
Open High Low Volume
$4.23 $4.49 $4.17 95547
Last updated 15.59pm 22/11/2024 ?
MYX (ASX) Chart

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Scientific conference spotlights PYC's work on blindness disease treatment PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M HotCopper users have reacted to overnight reports Dubber has seen $26M disappear from its coffers due to organised crime links.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.